When Other Health Conditions Tag Along With Hidradenitis Suppurativa

When other chronic illness tag along with hidradenitis suppurativa (HS), it can be quite difficult. You might have HS and, for example, post-traumatic stress disorder (PTSD) or polycystic ovary syndrome (PCOS). These chronic illnesses can be traumatic enough, but when you also have HS, it can be overwhelming and scary to try and cope with both at the same time.  

My PTSD started when I was young due to bullying, and it got worse through the school years. After my school years were over, I thought my PTSD had ended. But when I was diagnosed with HS after many trips to the urgent care clinic, my PTSD symptoms started coming back again. I would get so anxious and panicked about having another HS flare-up. Stress from my job also made my PTSD symptoms worse — and, stress from work also made my HS symptoms worse. 

It was difficult to manage both PTSD and HS at the same time. My mother, who is a nurse, helped me take care of my flare-ups and my emotional trials of pain and feeling mentally and physically weak. When I’d have an HS flare up, it would take all the energy out of me and I would feel physically and spiritually drained because of the pain. It felt like my emotions were on the verge of overflowing over my body. There were times I’d get three to four hours of sleep a night, or no sleep due to my emotional state combined with the pain of HS.

Related:The Challenges I Face At Work As Someone With Hidradenitis Suppurativa

In my case, I ended up quitting my job that was causing me stress, and found another job a couple of years later. My HS has been in remission for about four years. I still worry if I’m going to have another flare-up or not. I’m lucky that I haven’t had a flare-up except for a few scares here and there throughout the years. 

My sister in law has HS as well as PCOS. PCOS is a disorder characterized by growths on the ovaries and ovarian dysfunction. This hormonal imbalance can lead to irregular period cycles, acne, or facial hair. I know she’s going through a tough road and I know she and her husband are very strong on this journey. Her journey began when she was in the hospital after difficulty from surgery, to the point where she was septic from the HS. From what I can see in her eyes, she’s in pain, but she’s fighting and not giving up on her future of starting a family of her own one day. She’s just taking it one day at a time and one symptom at a time. 

Related:What Medical Professionals Often Get Wrong About Hidradenitis Suppurativa

Having one or more chronic illnesses along with hidradenitis suppurativa can be worrying and stressful, because it means going to doctor appointments, to see your counselor, your OB/GYN, or your dermatologist, while trying to live a somewhat normal life. It’s hard at times to keep things in line, but here are some ways I try to get through in my daily life. I make Post-It notes to remind myself to do certain things such as grocery shopping and making appointments and calls. That may seem stressful, but it’s easier said than done at times. I just take it day by day, especially since I work part-time at the moment. 

I also recommend talking to others, such as your spouse, caregiver, nurse, or physician. You can seek a professional counselor, or you can find a support group in your community or on social media, like I did a few years back when I was finally diagnosed after a few trips to the urgent care clinic. 

Related:The Battle to Adhere to Beauty Standards When You’re Chronically Ill

Having HS with a combination of other chronic illnesses can be stressful and it may be hard to focus on several symptoms at once. My advice is to take it one symptom at a time and treat it the best you can, no matter how hard it is.

Read more stories like this on The Mighty:

5 Questions I Wish I Had Asked When I Was Diagnosed With Hidradenitis Suppurativa

How You and I Can ‘Bring Hidradenitis Suppurativa to Light’

Trying to Plan for the Future With Chronic Illness

Source link

Hidradenitis Suppurativa Treatment Market 2019 Business Scenario – GlaxoSmithKline, Johnson & Johnson, Merck – Vital News 24

The recent published research report sheds light on critical aspects of the global Hidradenitis Suppurativa Treatment market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Hidradenitis Suppurativa Treatment market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Hidradenitis Suppurativa Treatment market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Ask for sample: www.statsandreports.com/request-sample/294592-global-hidradenitis-suppurativa-treatment-market-size-status-and-forecast-2019-2025

Key Segments Studied in the Global Hidradenitis Suppurativa Treatment Market 

Segment Details
Market Analysis By Type Medications, Surgery and Others
Market Analysis By Applications Hospitals, Clinics and Others
Market Analysis By Regions North America, United States, Canada, Mexico, Europe, Germany, France, UK, Italy, Russia, Asia-Pacific, China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Central & South America, Brazil, Middle East & Africa, Turkey, GCC Countries, Egypt and South Africa
Market Analysis By Companies GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Allergan, AstraZeneca

The recent published study includes information on key segmentation of the global Hidradenitis Suppurativa Treatment market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Hidradenitis Suppurativa Treatment market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Hidradenitis Suppurativa Treatment market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Read detail report: www.statsandreports.com/report/294592-global-hidradenitis-suppurativa-treatment-market-size-status-and-forecast-2019-2025 

Sample Table: Global Hidradenitis Suppurativa Treatment Market Size By Regions (USD Million) (2014-2025) 

Regions 2014 2016 2018 2020 2022 2024 2025 CAGR % 

Research Methodology

The research report has been prepared by conducting various rounds of primary interviews with key management of several Tier-I and II companies. The primary research percentage of all of reports are above ~80% whereas ~20% of secondary research includes data from hoovers, factiva, one source avention and other government published records. Both top-down approach has been applied for the calculation of market size, volume, import and export and has been validated thoroughly.

Ask for the discount: www.statsandreports.com/check-discount/294592-global-hidradenitis-suppurativa-treatment-market-size-status-and-forecast-2019-2025

The report on the global Hidradenitis Suppurativa Treatment market covers 12 sections as given below:

1. Industry Overview of Hidradenitis Suppurativa Treatment: This section covers market definition, classifications, specifications, applications, and market segmentation by region.

2. Hidradenitis Suppurativa Treatment Cost Structure Analysis: Here, raw materials and suppliers, industry chain structure, process analysis, and manufacturing cost structure analysis are covered.

3. Technical Data and Manufacturing Plants Analysis: In this section, the report provides capacity and commercial production date of Hidradenitis Suppurativa Treatment, manufacturing plants distribution, major manufacturers in 2018, raw material sources and technology sources analysis, and R&D status.

4. Overall Overview of Global Hidradenitis Suppurativa Treatment Market: It covers 2014-2018 overall market analysis, sales price analysis, capacity analysis, and sales analysis.

5. Hidradenitis Suppurativa Treatment Regional Market Analysis: The report includes a study on North America, China, Europe, Japan, Southeast Asia, and India Hidradenitis Suppurativa Treatment market analysis.

6. 2014-2018 Global Hidradenitis Suppurativa Treatment Market Segmentation Analysis by Type: This section covers Hidradenitis Suppurativa Treatment sales by type, interview price analysis of different types of Hidradenitis Suppurativa Treatment products and driving factors analysis of different types of Hidradenitis Suppurativa Treatment products.

7. 2014-2018 Global Hidradenitis Suppurativa Treatment Market Segmentation Analysis by Application: It includes Hidradenitis Suppurativa Treatment consumption by application, different applications of Hidradenitis Suppurativa Treatment products, and other studies.

8. Major Manufacturers Analysis of Global Hidradenitis Suppurativa Treatment Market: It provides analysis on each company profile with product pictures and specifications, sales, ex-factory price, revenue, gross margin analysis, and business distribution by region analysis.

9. Development Trend of Hidradenitis Suppurativa Treatment Market Analysis: Here, the report covers Hidradenitis Suppurativa Treatment market trend analysis, market size (volume and value) forecast, regional market trends, and market trends by product type and application.

10. Hidradenitis Suppurativa Treatment Marketing Type Analysis: It includes marketing type analysis, Hidradenitis Suppurativa Treatment market supply chain analysis, Hidradenitis Suppurativa Treatment international trade type analysis, and Hidradenitis Suppurativa Treatment traders or distributors by region with their contact information.

11. Consumers Analysis of Global Hidradenitis Suppurativa Treatment Market: This section explains consumer behavior and provides deep insights into various types of consumers in the global Hidradenitis Suppurativa Treatment market.

12. The conclusion of Global Hidradenitis Suppurativa Treatment Market Research Report 2018: It includes information on methodology, analyst introduction, and data sources.

Buy this Report: www.statsandreports.com/placeorder?report=294592-global-hidradenitis-suppurativa-treatment-market-size-status-and-forecast-2019-2025

About Us

Stats and Reports is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in today’s competitive environment and thus, we have collaborated with industry’s leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Stats and Reports
Satish K. (Global Sales Manager)
Mangalam Chamber, Office No – 16, Paud Road
Sankalp Society, Kothrud, Pune, Maharashtra 411038
Phone: +1 650-646-3808
Email: [email protected]
Web: https://www.statsandreports.com
Follow Us on: LinkedINTwitter|

Source link

The Challenges I Face At Work As Someone With Hidradenitis Suppurativa

I timidly knocked on my boss’s door, dreading the conversation that was going to happen in just a few moments. After five months of 10- to 12-hour days filled with chaos, my body had given out. My hidradenitis suppurativa (HS) was flaring up worse than it ever had before. I had lesions all over my body — both underarms, on my breasts, in my groin area — and I could barely walk. I masked the pain with a smile and hid in the bathroom when I could, so I could just break down and cry as I changed the gauze dressing under my arms that were leaking pus and blood. I was also battling intense clinical depression and generalized anxiety disorder. 

“Hey, I need to talk to you about something important.” My boss looked up with concern in his eyes. I was very fortunate that he knew about my HS and had tried his best to accommodate my pain, letting me work from home on occasion and giving me time off for doctor’s appointments. “I have to give my two weeks notice. My mental and physical health has declined so much that I’m not able to do my job. I need to take some time off to focus on my health. I’m really sorry.” He told me he was really bummed and would miss having me as his assistant, but he understood, which I was really grateful for.

Related:What Medical Professionals Often Get Wrong About Hidradenitis Suppurativa

At this point, I had been working in the entertainment industry for three years. I absolutely loved the work, but I knew it wasn’t sustainable. I couldn’t continue with the hours and unpredictability. Before moving to LA, I had dreams of being a TV news reporter, but I moved on from that dream after doctors and a college professor with HS told me stress can cause flare-ups. I worked other jobs, but I couldn’t shake my new dream of moving to LA to work in television. I knew I had to try. 

My first job in LA was an office job with pretty decent hours, but I still faced so many challenges. Getting dressed was always an hour-long process. What could I wear that looks professional but covers up my lesions? What is going to keep me cool but covered up? I always loaded up tissue paper just in case something started bleeding or oozing puss. All day long, I was conscious of where my arms were and who could see what. It made it difficult to concentrate on my job. Plus, sitting for eight hours a day put a lot of pressure on the boils on my butt. 

Related:The Battle to Adhere to Beauty Standards When You’re Chronically Ill

In November 2017, after leaving my last entertainment job, I took a long break and went back to Wisconsin to reevaluate my life and rest. I rediscovered my love for writing and started to share my personal story of life with HS, depression, and anxiety. I felt useful again. I returned to LA in January 2018 with writing assignments and a flexible, remote job where I could make my own hours and work part-time. 

Working from home has allowed me to take naps, wear comfortable clothing, and continue to focus on getting better, physically and mentally. If I’m in a lot of pain, I can take the day off. I found an HS clinic at UCLA with one of the top doctors. I am able to try new treatments that are more time-intensive, like infusions and surgery. There are days when I get angry at my disease and the time it’s stolen from me or the dreams I’ve had to give up on. I feel like I lost my 20s and no one understands what I’m going through. Most days, I feel like I am at war with my body. I see others in tank tops and shorts, and I desperately want to be like them. But there are some days when my burden feels like a gift, one that has allowed me to connect with others and better understand their pain.

Related:5 Questions I Wish I Had Asked When I Was Diagnosed With Hidradenitis Suppurativa

I’ve even found my life’s purpose thanks to HS. I will be getting my Master’s in marriage and family therapy. I want to specialize in chronic pain, chronic illness, and medical trauma. HS has increased my capacity for empathy. I know what it’s like to not be understood by doctors, bosses, friends, family, etc. I understand the pain of trying to live out your dreams while being stuck in a body that doesn’t work correctly. I know school is going to be very challenging, but this time, I feel confident that I will be able to pursue my dreams while taking care of myself. I may have to go slower than others, but life’s not a race.

Read more stories like this on The Mighty:

How You and I Can ‘Bring Hidradenitis Suppurativa to Light’

Trying to Plan for the Future With Chronic Illness

What It’s Like Having Hidradenitis Suppurativa

Source link

Ones to Watch: HidraMed Solutions look to commercialise innovative wound dressing across …

… system that will dramatically improve the wound care regime for people living with a debilitating disease called Hidradenitis Suppurativa (HS).

Source link

ChemoCentryx (CCXI) PT Raised to $60 at H.C. Wainwright

January 24, 2020 7:24 AM EST

Send to a Friend

H.C. Wainwright analyst Edward White raised the price target on ChemoCentryx (NASDAQ: CCXI) to $60.00 while maintaining a Buy rating.The …

This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Source link

Data Are Mixed for Using Zinc to Treat Inflammatory Skin Conditions

Zinc supplementation may be a potential adjunctive approach for several major inflammatory skin diseases, including acne vulgaris and atopic dermatitis, yet clinical evidence of the benefit of zinc in these disorders is mixed. This is according to data from preliminary findings from small studies published in the American Journal of Clinical Dermatology.

The study was a systematic review of trials that evaluated zinc supplementation and associated disease-related outcomes in patients with acne vulgaris, atopic dermatitis, diaper dermatitis, hidradenitis suppurativa, psoriasis, and rosacea. In the review, a total of 22 studies, which included 1667 patients and evaluated zinc gluconate (10-90 mg/day), zinc sulfate (0.375-1.8 g/day), and zinc oxide (0.012 g/day), were included.

In the 9 studies that compared zinc with placebo in patients with acne, there was an overall trend in favor of zinc supplementation. Although another study found zinc supplementation plus lactoferrin and vitamin E was associated with significant reductions in comedones and inflammatory lesions, researchers were unable to determine whether the causative factor was the zinc alone, or the combination of the zinc with lactoferrin and vitamin E. Compared with zinc, antibiotics demonstrated superior efficacy for acne management in 3 studies.

Findings varied in 2 studies that evaluated oral zinc for atopic dermatitis, with 1 study showing no beneficial effect vs placebo, and the other study showing a potential benefit of zinc for reducing disease severity. In another study of patients with rosacea, no significant difference was observed between oral zinc sulfate and placebo. This study resulted in early termination, as zinc was found to be less efficacious than placebo.

Limitations of the studies included in this review included the small sample sizes and the use of placebos containing ingredients that may lead to worsening of acne.

Although zinc appears to possess anti-inflammatory properties that may theoretically result in clinical improvements in some dermatologic conditions, the investigators noted that zinc supplementation “may not be universally beneficial in dermatologic inflammatory disease.”

Follow @DermAdvisor


Dhaliwal S, Nguyen M, Vaughn AR, Notay M, Chambers CJ, Sivamani RK. Effects of zinc supplementation on inflammatory skin diseases: a systematic review of the clinical evidence [published online November 19, 2019]. Am J Clin Dermatol. doi:10.1007/s40257-019-00484-0

Source link

Could This Ease to Speed Relief – The Market Journal

HTF MI added a new research study in its database with title ‘Hidradenitis Suppurativa – Pipeline Review, H1 2020’ that includes detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes North America ,United States ,South America ,MEA and important players/vendors such as Suppurativa (Dermatology,mechanism of action (MoA,route of administration (RoA) etc.The report will help user gain market insights, future trends and growth prospects for forecast period of 2019 – 2024

Request a sample report @ https://www.htfmarketreport.com/sample-report/2455722-hidradenitis-suppurativa-pipeline-review-1

Hidradenitis Suppurativa – Pipeline Review, H1 2020


Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa – Pipeline Review, H1 2020, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 13, 4, 5 and 5 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

AbbVie Inc
Aclaris Therapeutics Inc
Alvotech ehf
Amgen Inc
AstraZeneca Plc
ChemoCentryx Inc
Foamix Pharmaceuticals Ltd
Ichnos Sciences Inc
Immunwork Inc
Incyte Corp
InflaRx NV
Innovation Pharmaceuticals Inc
InSight Biopharmaceuticals Ltd
Johnson & Johnson
NeuClone Pty Ltd
Novartis AG
Pfizer Inc
Siam Bioscience Co Ltd
Staidson (Beijing) Biopharmaceuticals Co Ltd

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/2455722-hidradenitis-suppurativa-pipeline-review-1

Table of Contents
Hidradenitis Suppurativa – Overview
Hidradenitis Suppurativa – Therapeutics Development
Hidradenitis Suppurativa – Therapeutics Assessment
Hidradenitis Suppurativa – Companies Involved in Therapeutics Development
Hidradenitis Suppurativa – Drug Profiles


View Detailed Table of Content @ https://www.htfmarketreport.com/reports/2455722-hidradenitis-suppurativa-pipeline-review-1

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Place a Purchase Order For Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=2455722

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218

Connect with us at LinkedIn | Facebook | Twitter

Source link

Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa | Dermatology | JAMA Dermatology

Hidradenitis suppurativa (HS) has been associated with a high prevalence of spondyloarthritis; however, the population-based risk of developing inflammatory arthritis remains unclear.1 This population-based cohort study sought to evaluate the risk of developing inflammatory arthritis among patients with HS compared with matched patients without HS.

We used longitudinal claims data from commercially insured patients, including those with Medicaid and Medicare, covering 185 million lives in the United States between January 1, 2003, and January 1, 2016. We identified patients of all ages who received a diagnosis of HS (International Classification of Diseases, Ninth Revision code 705.83 or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision code L73.2), defined as 1 diagnosis by a dermatologist or 3 diagnoses by any health care professional.2 The cohort entry date for the HS group was the first recorded diagnosis date of HS after at least 180 days of continuous enrollment (eFigure in the Supplement). For the non-HS group, we risk-set sampled 2 patients without HS from all plan enrollees who did not have a diagnosis of HS matched on the date the patient with HS entered the cohort. We excluded patients who had less than 180 days of continuous enrollment before cohort entry or had preexisting inflammatory arthritis, including ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis, or rheumatoid arthritis (eAppendix in the Supplement). The Brigham and Women’s Hospital’s Institutional Review Board approved this study. All patient information was deidentified.

Source link

Hidradenitis Suppurativa May Precede Inflammatory Arthritis

A diagnosis of hidradenitis suppurativa may precede the development of ankylosing spondylitis, psoriatic arthritis or rheumatoid arthritis in patients, …

Source link

Reviewing Audentes Therapeutics Inc. (BOLD)’s and XBiotech Inc. (NASDAQ:XBIT)’s results

Both Audentes Therapeutics Inc. (NASDAQ:BOLD) and XBiotech Inc. (NASDAQ:XBIT) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Audentes Therapeutics Inc. 60 -1.09 36.99M -3.98 0.00
XBiotech Inc. 19 0.00 25.44M -0.64 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 has Audentes Therapeutics Inc. and XBiotech Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Audentes Therapeutics Inc. 62,022,132.80% -42.6% -38%
XBiotech Inc. 134,106,483.92% -45.2% -43.1%

Risk and Volatility

Audentes Therapeutics Inc. is 38.00% more volatile than Standard & Poor’s 500 because the company has a beta of 1.38. Competitively, XBiotech Inc. is 53.00% less volatile than Standard & Poor’s 500, because of the 0.47 beta.


Audentes Therapeutics Inc. has a Current Ratio of 12.8 and a Quick Ratio of 12.8. Competitively, XBiotech Inc.’s Current Ratio is 20.2 and has 20.2 Quick Ratio. XBiotech Inc.’s better ability to pay short and long-term obligations than Audentes Therapeutics Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Audentes Therapeutics Inc. and XBiotech Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Audentes Therapeutics Inc. 0 5 0 2.00
XBiotech Inc. 0 0 1 3.00

Audentes Therapeutics Inc.’s downside potential is -16.62% at a $50 average price target. On the other hand, XBiotech Inc.’s potential upside is 21.69% and its average price target is $28. The information presented earlier suggests that XBiotech Inc. looks more robust than Audentes Therapeutics Inc. as far as analyst belief.

Institutional and Insider Ownership

The shares of both Audentes Therapeutics Inc. and XBiotech Inc. are owned by institutional investors at 0% and 24.8% respectively. About 1.1% of Audentes Therapeutics Inc.’s share are held by insiders. Competitively, XBiotech Inc. has 43.46% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Audentes Therapeutics Inc. 104.1% 121.5% 93.37% 59.1% 146.77% 177.91%
XBiotech Inc. -3.22% 7.34% 24.94% 54.66% 171.22% 118.9%

For the past year Audentes Therapeutics Inc. has stronger performance than XBiotech Inc.


XBiotech Inc. beats on 7 of the 12 factors Audentes Therapeutics Inc.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link